AZ signs deal with Europe's IVA for coronavirus vaccine supply
AstraZeneca has agreed with Europe’s Inclusive Vaccines Alliance (IVA) that it will supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine to broaden access in the region.
The deal, which will see deliveries start by the end of this year, allows the IVA aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the initiative.
“This agreement will ensure that hundreds of millions of Europeans have access to Oxford University’s vaccine following approval,” said Pascal Soriot, AZ' chief executive.
Read more: http://www.pharmatimes.com/news/az_signs_deal_with_europes_iva_for_coronavirus_vaccine_supply_1342267
The deal, which will see deliveries start by the end of this year, allows the IVA aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the initiative.
“This agreement will ensure that hundreds of millions of Europeans have access to Oxford University’s vaccine following approval,” said Pascal Soriot, AZ' chief executive.
Read more: http://www.pharmatimes.com/news/az_signs_deal_with_europes_iva_for_coronavirus_vaccine_supply_1342267